Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

IDEXX Laboratories: Strong Instrument Placement Drives Q1

Published 05/30/2016, 08:12 AM
Updated 07/09/2023, 06:31 AM

On May 30, we issued an updated research report on Delaware, NJ-based IDEXX Laboratories, Inc. (NASDAQ:IDXX) – a manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company currently carries a Zacks Rank #2 (Buy).

IDEXX started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate. Strong instrument placements, global lab momentum reflecting the company’s leverage of expanded commercial capability as well as strong test menu expansion were some of the key highlights for IDEXX’s business at the start of 2016.

Moreover, IDEXX continued to demonstrate solid growth globally with strong international expansion as is evident from the double digit organic revenue growth observed in the overseas. Moreover, during the first quarter, the company successfully placed 714 catalysts and 1,150 premium instruments in its international market.

Strong consumable revenue growth owing to high levels of instrument placements as well as improved lab revenue gains primarily drove this overseas growth. Management was particularly upbeat about the continued growth observed in premium instrument placements.

With respect to its Companion Animal Group (CAG) segment, IDEXX witnessed strong recurring Diagnostic gains across the U.S., Canada, Europe, Asia Pacific and Latin America. Moreover, the company noticed moderate growth in net customer acquisition cost, reflecting its success in differentiating its diagnostic technologies from competitive offerings. The company also holds a strong cash balance position.

On the flip side, foreign currency headwinds are a major issue, with approximately 38% of IDEXX’s sales coming from overseas. Evidently, foreign exchange fluctuations affected the company’s revenue growth in the first quarter by 2% and EPS by $0.05 per share, including the impact from the 2015 hedge gains.

Moreover, the instrument consumables and rapid assay products in the company’s CAG segment are often sold by third-party distributors. Unfavorable distributor purchasing dynamics can affect the company’s sales growth for these products. Competitive headwinds also pose threat to the stock.

Key Picks in the Sector

Better-ranked medical stocks are Baxter International Inc. (NYSE:BAX) , Boston Scientific Corporation (NYSE:BSX) and SurModics, Inc. (NASDAQ:SRDX) . While Baxter sports a Zacks Rank #1 (Strong Buy), Boston Scientific and SurModics carry a Zacks Rank #2.



IDEXX LABS INC (IDXX): Free Stock Analysis Report

BOSTON SCIENTIF (BSX): Free Stock Analysis Report

BAXTER INTL (BAX): Free Stock Analysis Report

SURMODICS (SRDX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.